Demographics and baseline characteristics
| Parameter . | Baseline value, n = 97 . |
|---|---|
| Sex, no. (%) | |
| Male | 48 (49.5) |
| Female | 49 (50.5) |
| Race, no. (%) | |
| White | 88 (90.7) |
| Other | 9 (9.3) |
| Median age, y (range) | 41 (18–78) |
| Median duration of PNH, y (range) | 4.9 (0.1–31.4)* |
| Median packed RBC transfused 12 mo prior to screening, units (range) | 8.0 (0.0–66.0) |
| Median platelet count, 109/L (range) | 136 (23–355) |
| Median PNH type III RBC clone, % (range) | 33.5 (7.7–98.8) |
| Median RBC count, 1012/L (range) | 2.8 (0.5–4.8) |
| Median reticulocyte count, % (range) | 4.9 (1.4–24.5) |
| Median hemoglobin levels, g/L (range) | 93 (48–131) |
| Median LDH, U/L (range) | 2051 (537–5245) |
| History of thrombosis, no. (%) | 42 (43) |
| Pretreatment events, no. | 91 |
| Parameter . | Baseline value, n = 97 . |
|---|---|
| Sex, no. (%) | |
| Male | 48 (49.5) |
| Female | 49 (50.5) |
| Race, no. (%) | |
| White | 88 (90.7) |
| Other | 9 (9.3) |
| Median age, y (range) | 41 (18–78) |
| Median duration of PNH, y (range) | 4.9 (0.1–31.4)* |
| Median packed RBC transfused 12 mo prior to screening, units (range) | 8.0 (0.0–66.0) |
| Median platelet count, 109/L (range) | 136 (23–355) |
| Median PNH type III RBC clone, % (range) | 33.5 (7.7–98.8) |
| Median RBC count, 1012/L (range) | 2.8 (0.5–4.8) |
| Median reticulocyte count, % (range) | 4.9 (1.4–24.5) |
| Median hemoglobin levels, g/L (range) | 93 (48–131) |
| Median LDH, U/L (range) | 2051 (537–5245) |
| History of thrombosis, no. (%) | 42 (43) |
| Pretreatment events, no. | 91 |
All patients met the enrollment inclusion criteria during at least one visit of the screening period, which preceded the baseline measurements.
RBC indicates red blood cell; and LDH, lactate dehydrogenase.
One patient had a diagnosis of PNH confirmed less than 6 months prior to the study, however, the patient's medical history supported that PNH was present for at least 6 months prior to the study.